Albendazole has antiparasitic broad spectrum activity against nematodes and platyhelminths. The primary mechanism of action involves the inhibition of tubulin polymerization. Albendazole is active against the human threadworm (Enterobius vermicularis), human whipworms (Trichuris trichiura), human roundworm (Ascaris lumbricoides), hookworm duodenum (Ancylostoma duodenale), American hookworm (Necator americanus), intestinal nematode (Strongyloides stercoralis), and certain tapeworms (Taenia spp.).
Albendazole is poorly absorbed from the gastrointestinal tract (<5%); meal increases the absorption. As a result of intensive and rapid first-pass effect in the plasma concentrations of albendazole is virtually undetectable. Albendazole is metabolized in the liver to pharmacologically active sulfoxide. High concentrations of albendazole sulfoxide in the plasma there are about 2-5 hr after dosing. Albendazole sulfoxide in 70% bound to plasma proteins, the t1 / 2 of 8.5 h and is mainly excreted in the bile, also in small quantities in the urine. In studies in rats and rabbits albendazole was teratogenic and embryotoxic.
The treatment of single or mixed invasion caused by threadworm human whipworms human, human worm, hookworm duodenal, American hookworm, tapeworm and nematode intestinal tapeworm unarmed and armed.
Hypersensitivity to any component of the formulation or suspected pregnancy. In women of childbearing potential use of the drug is limited to the first 7 days after the onset of menstruation or after obtaining a negative pregnancy test. Do not use in children under 2 years of age. Treatment with albendazole may disclose CNS cysticercosis, before extending symptoms, neurological symptoms (convulsions, increased intracranial pressure, focal symptoms) may occur soon after treatment, you may need to immediately start administering anticonvulsants and steroids.
Concurrent use of dexamethasone, praziquantel or cimetidine increases the plasma concentrations of albendazole. Ritonavir, phenytoin, carbamazepine and phenobarbital may decrease concentrations of the active metabolite of albendazole in serum; significance of this interaction is unknown, however, because of the risk of reducing the effectiveness of the drug should monitor the effectiveness of treatment, particularly when treating systemic infections and, if necessary, modify the dosage.
Category C. Do not use during pregnancy. Albendazole has harmful effects on the fetus and causes developmental defects in animals. In the course of treatment and one month after its completion should use effective methods of contraception. In women of childbearing age, treatment should be carried out during the first 7 days of menstruation or after a negative pregnancy test. Should not be used during breastfeeding unless the potential benefits outweigh the risks of treatment.
Adults and children after 2 years of age: p.o in the case of Enterobius vermicularis infection, Trichuris trichiura, Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus used 400 mg of the drug at once. In infections, Strongyloides stercoralis, Taenia spp and 400 mg is used drug for 3 consecutive days. In the absence of effect 3 weeks after treatment can be repeated.
Other resources: www.albendazole.pw
To avoid accidental use in early pregnancy, women of childbearing age should begin treatment with albendazole on the 1st week of menstruation or a negative pregnancy test result. Patients should be warned about the need to use effective methods of contraception during treatment with albendazole and for 1 month after its cancellation.
During treatment should monitor liver enzymes prior to each treatment cycle, and (preferably) every 2 weeks during treatment. If the rate is more than 2 times the upper limit of normal, treatment with albendazole should be discontinued until full normalization.